IL17A and rheumatoid arthritis: A clinical phase II study testing the efficacy of the IL-17A neutralizing antibody secukinumab demonstrated that long-term treatment of RA patients, who were non-responders to DMARDs or biologics, resulted in a clinical improvement (12).